• Why Attend?
  • Speakers
  • Contact Us

Why Attend?

Join Paradigm Health and The Cancer & Hematology Centers for a discussion on what it takes to successfully execute post-approval research in community care settings.

Through a real-world case study, speakers will share lessons learned from conducting prospective research within routine clinical care, including the operational challenges sites face, the realities of balancing research and patient care, and the factors that influence participation in post-approval studies.

Attendees will gain insight into what it takes to successfully embed post-approval research into routine care, including approaches to reducing site burden, improving patient identification and enrollment, and generating high-quality prospective evidence in real-world care settings.

Attendees will learn:

  • Challenges community sites face when participating in late-stage and post-approval research
  • Operational factors that influence study feasibility, enrollment, and site participation
  • Approaches to reducing workflow burden while maintaining research quality
  • Lessons learned from conducting prospective research within routine care settings
  • Considerations for broader patient participation and more representative evidence generation
  • Implications for future post-approval, pragmatic, and real-world evidence studies

 

Whether you are responsible for clinical development, medical affairs, real-world evidence, or clinical operations, this session will provide practical insights into how post-approval studies can be designed and executed in ways that better align with the realities of community care.

Why attend:

  • Identify the operational challenges that impact participation and execution of post-approval research in community oncology settings.
  • Describe approaches to integrating post-approval research into routine care through workflow-aligned patient identification, enrollment, and data collection processes.
  • Evaluate lessons learned from a real-world case study and their implications for scalable, high-quality evidence generation in late-stage and post-approval research.

Speakers

Select a speaker to learn more

Back
Anosheh Afghahi, M.D., M.P.H.
Senior Medical Director, Paradigm Health

Anosheh Afghahi, M.D., M.P.H., is a medical oncologist who specializes in breast and hereditary cancer syndromes. She is a Senior Medical Director at Paradigm Health, where she serves as the medical lead for tech-enabled prospective clinical trials and supports the patient-trial matching services across the Paradigm clinical research network.

Prior to joining Paradigm Health, Afghahi served as Medical Director at Flatiron Health, where she was the medical lead for their patient-trial matching service and worked closely with academic investigators on clinical research opportunities. Afghahi is an experienced clinician and serves as Clinical Assistant Professor at the University of Colorado, where she takes care of patients with breast cancer.

Prior to her transition to health technology, Afghahi worked full-time as Assistant Professor at the University of Colorado, where she served as principal investigator on several grant-funded investigator-initiated and national clinical trials. In addition, she was the medical director of the Hereditary Cancer Program and the Vice President of the Colorado Cancer Coalition.

Afghahi received a Medical Degree from Harvard Medical School and a Master of Public Health from Harvard School of Public Health.

Next speaker
Back
Joy Bartholomew, PhD
Senior Director of Research Operations, The Cancer & Hematology Centers

Joy Bartholomew, PhD, is the Senior Director of Research Operations at The Cancer & Hematology Centers (CHC), where she oversees Phase II-IV interventional and noninterventional clinical trials across seven community oncology locations throughout Michigan. Her career has spanned both clinical practice and research, focusing on improving outcomes for adult and pediatric cancer patients through clinical trials. Having led research operations in large metropolitan academic centers as well as rural community settings, Joy brings extensive experience operationalizing clinical research and integrating post-approval studies into routine oncology care.

Next speaker

Enquiry